Stock 600200 JIANGSU WUZHONG PHARMACEUTICAL DEVELOPMENT CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

News JiangSu WuZhong Pharmaceutical Development Co., Ltd.

Equities

600200

CNE000000YP4

End-of-day quote Shanghai S.E.
Other stock markets
 06:00:00 2024-05-30 pm EDT 		5-day change 1st Jan Change
10.08 CNY -2.80% Intraday chart for JiangSu WuZhong Pharmaceutical Development Co., Ltd. +1.51% +22.63%
Apr. 24 JiangSu WuZhong Pharmaceutical Development Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Apr. 24 JiangSu WuZhong Pharmaceutical Development Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Summary

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
JiangSu WuZhong Pharmaceutical Development Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
JiangSu WuZhong Pharmaceutical Development Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
JiangSu WuZhong Pharmaceutical Development Co., Ltd. cancelled the transaction announced on April 25, 2023
CI
JiangSu WuZhong Pharmaceutical Development Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023
CI
Jiangsu WuZhong Pharma to Invest 30 Million Yuan in Local Biotech Firm
MT
Wuzhong Pharmaceutical Development's Unit Gets Registration Certificate for Linezolid Sodium Chloride Injection
MT
JiangSu WuZhong Pharmaceutical Development Co., Ltd.(XSSC:600200) added to S&P Global BMI Index
CI
JiangSu WuZhong Pharmaceutical Development Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023
CI
JiangSu WuZhong Pharmaceutical Development Co., Ltd. cancelled the transaction announced on November 11, 2021
CI
JiangSu WuZhong Pharmaceutical Development Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022
CI
JiangSu WuZhong Pharmaceutical Development Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023
CI
JiangSu WuZhong Pharmaceutical Development Co., Ltd. announced that it expects to receive CNY 1.2 billion in funding from Zhejiang Fuji Holdings Group Co., Ltd. and other investors
CI
Cinkate Medicine Chemical Intermediate Co., Ltd. agreed to acquire 15% stake in Suzhou Changzheng Cinkate Pharmaceutical Co., Ltd. from JiangSu WuZhong Pharmaceutical Development Co., Ltd. for CNY 33 million.
CI
JiangSu WuZhong Pharmaceutical Development Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022
CI
JiangSu WuZhong Pharmaceutical Development Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022
CI
JiangSu WuZhong Pharmaceutical Development Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
JiangSu WuZhong Pharmaceutical Development Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021
CI
JiangSu WuZhong Pharmaceutical Development Co., Ltd. cancelled the transaction to acquire 70% stake in Shanghai Weina Cosmetics Co., Ltd., from Weina Hongkong Co., Limited.
CI
Jiangsu Wuzhong Pharmaceutical Group Corporation announced that it expects to receive CNY 340 million in funding from JiangSu WuZhong Pharmaceutical Development Co., Ltd.
CI
JiangSu WuZhong Pharmaceutical Development Co., Ltd. announced that it expects to receive CNY 300 million in funding from Suzhou Fuji Suwu Pharmaceutical Technology Partnership Enterprise (Limited Partnership)
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 600200 Stock
  4. News JiangSu WuZhong Pharmaceutical Development Co., Ltd.